Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years.

Impact · against what's priced in

The article provides historical context on the SCHD ETF's performance and its avoidance of growth stocks during the 2022 crash, but it contains no new material regarding the current fundamentals or catalysts for Tesla, Meta, or Amazon. Consequently, the mentions of these companies are purely retrospective and do not shift current price assumptions.

AMZN+0.00: Doesn't touch the price's assumptions
In context: The article cites Amazon's 50% drop in 2022 to illustrate the fund's defensive nature, which has no bearing on the current price's reliance on AWS acceleration and FCF margin expansion.

Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years.

What matters in this story

Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens

Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years.

What matters in this story

Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens

How each ticker is affected

Track these names every morning.

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH

History Says Abbott Stock Could More Than Double by 2036. Here's Why I Just Added It to My Portfolio.

AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.

History Says This 1 ETF Could Turn $1,000 Into $38,000 in 20 Years. Here's How.

Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years.

What matters in this story

Next reads from the same story arc

Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens

Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years.

What matters in this story

Next reads from the same story arc

Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens

How each ticker is affected

Track these names every morning.

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH

History Says Abbott Stock Could More Than Double by 2036. Here's Why I Just Added It to My Portfolio.

AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.

History Says This 1 ETF Could Turn $1,000 Into $38,000 in 20 Years. Here's How.